Please provide your email address to receive an email when new articles are posted on . Researchers found a median reduction in systolic blood pressure of 32 mm Hg. Results are consistent with ...
Amicus Therapeutics has released a post-hoc analysis from the PROPEL study, published in Muscle and Nerve, which evaluated the efficacy of cipaglucosidase alfa-atga combined with miglustat (cipa+mig) ...
The post hoc analysis of the AGAVE-201 trial found that axatilimab demonstrated consistent response rates in patients with chronic graft-vs-host disease (GVHD), regardless of the number or type of ...
In a post-hoc analysis of the ADVANCE and MOTIVATE phase III induction studies, along with the FORTIFY maintenance study, researchers evaluated the safety profile of risankizumab (Skyrizi) in patients ...
The findings suggest that treatment with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) led to improvements and had a similar safety profile to both FF/VI and UMEC/VI regardless of ...
A systematic review and network meta-analysis evaluating neoadjuvant treatments in muscle-invasive bladder cancer. Median OS from wk 9, mo (95% CI) 51.4 (36.9-NR) 17.5 (14.5-24.7) 5.9 (5.0-7.2) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results